Delving into the Latest Updates on RHYK-2008 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

RHYK 2008, RHYK-2008, RHYK2008

Target-

Mechanism-

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Essential Hypertension

Inactive Indication-

Originator Organization

Shijiazhuang Keren Medical Technology Co., Ltd.

Active Organization

Shijiazhuang Keren Medical Technology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：在健康受试者体内，空腹条件下，以Recordati S.P.A.持有的盐酸乐卡地平片（商品名：Zanidip®；规格：10 mg）为对照药，研究石家庄科仁医药科技有限公司研发的RHYK2008（规格：10 mg；试验药）的人体药代动力学，为后续临床试验提供依据。次要目的：观察健康受试者空腹口服试验药、对照药的安全性。

[Translation]

Primary objective: To study the pharmacokinetics of RHYK2008 (specification: 10 mg; experimental drug) developed by Shijiazhuang Keren Pharmaceutical Technology Co., Ltd. in healthy subjects under fasting conditions, using Lercanidipine Hydrochloride Tablets (trade name: Zanidip®; specification: 10 mg) owned by Recordati S.P.A. as the control drug, to provide a basis for subsequent clinical trials. Secondary objective: To observe the safety of fasting oral administration of experimental drugs and control drugs in healthy subjects.

Start Date19 Jan 2024

Sponsor / Collaborator

Shijiazhuang Keren Medical Technology Co., Ltd.

100 Clinical Results associated with RHYK-2008

Login to view more data

100 Translational Medicine associated with RHYK-2008

Login to view more data

100 Patents (Medical) associated with RHYK-2008

Login to view more data

100 Deals associated with RHYK-2008

Login to view more data